PANCREATIC CANCER

This study tests a new drug called ANO31905, given with standard chemotherapy, as a first treatment for people with a specific type of advanced pancreatic cancer (CLDN18.2-positive). The goal is to see if the combination is safe and helps shrink tumors. About 84 adults with cance…

This study tests whether adding the drug IBI343 to standard chemotherapy before surgery can help people with a specific type of pancreatic cancer that is on the edge of being removable. About 40 adults with CLDN18.2-positive tumors will receive 4 cycles of the combination, then s…

This early-stage trial tests whether adding three experimental drugs to standard chemotherapy can shrink pancreatic tumors enough to allow surgery. About 30 adults with borderline resectable or locally advanced pancreatic cancer will receive the combination before surgery, then c…

This early-phase study tests DCTY1102, a personalized cell therapy, in 18 adults with advanced colorectal, lung, or pancreatic cancers that have a specific KRAS/NRAS G12D mutation and HLA type. Participants receive a single infusion of their own genetically modified immune cells …

This study looks at a procedure called total pancreatectomy with islet autotransplantation (TPIAT) in 30 adults with pancreatic or nearby tumors who are at high risk for a leak after standard surgery. The goal is to see if removing the whole pancreas and transplanting the patient…

This study tests whether adding the drug adebrelimab to standard chemotherapy before surgery can help remove pancreatic cancer more completely. About 30 adults with resectable pancreatic cancer will receive the combination treatment. The goal is to see if this approach improves t…

This study tests a new drug called BHB810 in adults with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. The drug is given as an IV infusion every two weeks. The main goals are to check safety, find the best dose, and see if it …

This early-phase study tests whether adding the experimental drug NP137 to standard chemotherapy can change how pancreatic cancer cells behave. About 25 people with resectable pancreatic cancer will receive NP137 before surgery and then again with chemotherapy after surgery. The …

This study looks at whether adding diabetes medication to standard chemotherapy can help people with metastatic pancreatic cancer and diabetes live longer. About 210 adults will receive either chemotherapy alone or chemotherapy plus active diabetes treatment. The main goal is to …

This early-phase trial tests a new treatment for people with advanced pancreatic cancer whose tumors have stopped responding to chemotherapy. The therapy uses specially engineered immune cells (CAR-M) designed to recognize and attack cancer cells that have a protein called C-MET.…

This study tests whether adding focused ultrasound (IMD10) to standard chemotherapy can help people with borderline or locally advanced pancreatic cancer live longer. About 136 adults aged 18 to 85 with confirmed pancreatic cancer will be randomly assigned to receive chemotherapy…

This study tests whether a specific sequence of two different chemotherapy combinations, each paired with an immunotherapy drug (PD-L1 antibody), can shrink borderline resectable or locally advanced pancreatic cancer enough to allow surgical removal. About 77 adults with this typ…

This phase 3 study tests whether adding the experimental drug FG-M108 to standard chemotherapy helps people with a specific type of advanced pancreatic cancer live longer. The drug targets a protein called Claudin18.2 found on some cancer cells. About 524 adults with untreated ad…

This study tests a new approach for people with locally advanced pancreatic cancer. Tiny radioactive rods are placed directly into the tumor to deliver alpha radiation, combined with standard chemotherapy. The main goal is to check safety, but researchers will also see if the tre…

This early-stage trial tests an experimental drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goal is to check the drug's safety and find the best dose. Researchers will also look for signs that the drug shrinks tum…

This early-phase trial tests a new combination treatment for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered immune cells (NK cells) from donated cord blood, given both into the belly and through a ve…

This study looks at whether adding a constipation capsule (Shouhui Tongbian) to standard pancreatic enzyme pills can improve digestion in people who had part of their pancreas removed due to cancer. About 80 adults will take the combination for 12 weeks. The goal is to see if it …

This study tests an experimental drug called HRS-7058 in people with advanced pancreatic cancer that has a specific change in the KRAS gene (G12C mutation). Participants must have already tried at least one other cancer treatment. The goal is to see if the drug can shrink tumors …

This study tests a new oral drug, BLEX 404, combined with standard chemotherapy (gemcitabine) in 40 adults with advanced pancreatic cancer that cannot be removed by surgery or has spread. The goal is to find a safe dose and see if the combination shrinks tumors. Participants must…

This study will test a new scoring system called OC26 to see if it can more accurately diagnose autoimmune pancreatitis, a condition where the immune system attacks the pancreas. Researchers will look at data from 82 adults with suspected autoimmune pancreatitis, including their …

This study tests a special PET scan that looks for a protein called Claudin18.2 on pancreatic and stomach cancer cells. The goal is to see if this scan can accurately find the protein, helping doctors choose the right targeted treatment for each patient. About 64 adults with thes…

This study tests a new type of PET scan that uses a special probe to find cancers that have a protein called GPA33. The study will include 56 people with suspected or confirmed colorectal, stomach, or pancreatic cancer, as well as healthy volunteers. The goal is to see if this im…

This study tests whether a probiotic called Clostridium butyricum CBM588 can reduce diarrhea and improve quality of life in 158 adults after pancreatic surgery. Participants will receive either the probiotic or a placebo for a set period. The goal is to see if this supplement hel…

This study is testing a new web-based program designed to help people with pancreatic cancer reduce stress and manage symptoms like pain, fatigue, and sleep problems. Researchers will enroll 60 adults who speak English or Spanish to see if the program is easy to use and helpful. …

This study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers. About 98 adults will be randomly assigned to either the exercise program or standard follow-up. The main goals …

This study tests whether a 12-week supervised strength training program can help people with advanced pancreatic cancer preserve muscle mass and improve quality of life. Ten participants will be randomly assigned to either the exercise program or standard care. The goal is to see…

This study will track 2,500 adults in Italy who are having an endoscopic ultrasound (EUS) because doctors suspect they have pancreatic or bile duct cancer. Researchers want to see how accurate the tissue samples taken during EUS are, how safe the procedure is, and how quickly pat…

This study will create a biobank by collecting blood, tissue, and other samples from 300 people with liver, bile duct, or pancreatic tumors, as well as from people with benign conditions and healthy volunteers. No experimental treatments or extra procedures are involved—samples a…

This study will create a large database of 1,000 people with a specific type of pancreatic cancer (KRAS-mutant). Researchers will track how long patients live and how long their cancer stays under control after receiving targeted therapy. The goal is to better understand which tr…

This study looks at whether tumor DNA found in blood or belly fluid can predict if stomach, colon, or pancreatic cancer will spread to the lining of the abdomen (peritoneum). Researchers will follow 300 patients with early-stage cancers to see if those with positive tumor DNA hav…

This study looks at whether intermittent fasting (eating only during certain hours) is safe and doable for 20 people at high risk for pancreatic cancer. Researchers will check for side effects and see if fasting changes markers in the blood, gut bacteria, or imaging scans. The go…

This study interviews 20 pancreatic cancer patients to learn why certain groups—like racial minorities, people with lower incomes, rural residents, or non-English speakers—are less likely to join clinical trials. Researchers hope to find ways to make trials more accessible and fa…

This study looks at whether tumor cells found in the portal vein (a major liver blood vessel) can warn early if pancreatic cancer comes back or spreads. Researchers will test 20 people with removable or borderline-removable pancreatic cancer. The goal is to improve monitoring and…

This study looks at whether analyzing tumor cells found in the blood can help predict how well certain cancer drugs (PARP inhibitors and chemotherapy) will work. Researchers will collect blood samples from 300 adults with advanced breast, prostate, pancreatic, or ovarian cancer. …

This study compares two ways surgeons reconnect the stomach and intestines after removing part of the pancreas for cancer. The goal is to see which method causes fewer problems with stomach emptying after surgery. About 124 adults having this operation will be randomly assigned t…